Another study used GRP94 or gp96 monoclonal antibody (gp96 mAb) to interrupt the HER2 dimerization and phosphorylation in breast cancer, which lead ultimately to inhibiting their growth and proliferation both in vitro and in vivo [215]. This evidence concerns the gene HSP90B1 and breast carcinoma.